Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Huntley

Neurology Dunedin, FL Medical Doctor

NPI 1356440366 CMS profile 60911

1330 Pinehurst Rd, Dunedin, FL 34698

Open in the dashboard

General payments

$1,928

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Huntley of Dunedin, FL is reported in the CMS Open Payments database as having received $1,928 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34 2
2024 General $129 7
2023 General $301 16
2022 General $366 20
2021 General $445 28
2020 General $343 16
2019 General $309 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Huntley
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to William Huntley were reported at $34. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year William Huntley Neurology median Middle half National median
2019 $309 $474 $118–$2,177 $163
2020 $343 $367 $82–$2,309 $114
2021 $445 $438 $104–$2,547 $132
2022 $366 $442 $103–$2,388 $149
2023 $301 $464 $119–$2,312 $160
2024 $129 $468 $119–$2,323 $164
2025 $34 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $215 13 payments
  2. Amgen Inc. $204 8 payments
  3. Novartis Pharmaceuticals Corporation $186 10 payments
  4. Lilly USA, LLC $173 10 payments
  5. Teva Pharmaceuticals USA, Inc. $108 6 payments
  6. UCB, Inc. $99 6 payments
  7. Biogen, Inc. $84 6 payments
  8. Eisai Inc. $78 4 payments
  9. Biohaven Pharmaceuticals, Inc. $77 4 payments
  10. AstraZeneca Pharmaceuticals LP $69 4 payments
  11. Other $636 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,928 109 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $331 15 payments
  2. QULIPTA $117 7 payments
  3. EMGALITY $105 6 payments
  4. NURTEC ODT Primary Care $104 6 payments
  5. UBRELVY Neuroscience $87 5 payments
  6. Vimpat $75 5 payments
  7. NURTEC ODT Pain $63 3 payments
  8. NEURACEQ $59 4 payments
  9. REYVOW $56 3 payments
  10. UBRELVY Neuroscience $56 3 payments
  11. Other $978 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

813

Median for Neurology: 833

Drug cost

$59,197

Median for Neurology: $202,670

Branded share of claims

25.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Glatopa Glatiramer Acetate Brand 13 $25,351
Lamotrigine Odt Lamotrigine Brand 13 $5,827
Levetiracetam Generic 141 $5,550
Memantine Hcl Generic 132 $4,512
Rivastigmine Rivastigmine Tartrate Brand 50 $3,087
Carbamazepine Er Carbamazepine Brand 13 $2,815
Memantine Hcl Er Memantine Hcl Brand 27 $2,774
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 25 $1,705
Gabapentin Generic 60 $1,573
Primidone Generic 53 $1,252

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$66,291

Medicare's payments for the services billed

Medicare patients

363

Average age 77

Services billed

713

209 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 55%
Depression 50%
Chronic kidney disease 46%
Alzheimer's or dementia 37%
Diabetes 36%
Heart failure 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $38
$38 — —
NURTEC ODT
  • PFIZER INC. $20
$20 — —
ZAVZPRET
  • PFIZER INC. $20
$20 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $17
$17 — —
VYEPTI
  • Lundbeck LLC $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record